There is an association between contact allergy to aluminium and persistent subcutaneous nodules in children undergoing hyposensitization therapy

Netterlid, Eva; Hindsén, Monica; Björk, Jonas; Ekqvist, Susanne; Güner, Nuray; Henricson, Kent Ake; Bruze, M.

doi:10.1111/j.1600-0536.2008.01474.x

Cited by 57 publications

(73 citation statements)

References 20 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[189][190][191][192] For aluminum hydroxide containing SCIT products, granulomas have been described from a foreign body reaction mainly caused by incorrect intradermal administration as well as contact allergic reactions, new onset of protein contact dermatitis, or a vasculitis inflammatory reactions have been reported. [193][194][195] If these reactions to SCIT occur, treatment with another aluminum hydroxide-free product is preferred (Grade D). 11 …”

Section: Scitmentioning

confidence: 99%

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Roberts

Pfaar

Akdiş

et al. 2017

Allergy

564

705

View full text Add to dashboard Cite

drawn on data from a systematic review of the literature, more recent published studies and multistakeholder expert clinical opinion. This Guideline is aimed at healthcare professionals who are encouraged to take the recommendations into account in the context of delivering clinical care. This Guideline is not a substitute for professional clinical judgment, which professionals need to exercise in the context of delivering personalised healthcare. AbstractAllergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project "EAACI Guidelines on Allergen Immunotherapy." It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach.The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass 766 | ROBERTS, PFAAR ET AL. tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children. | ME TH ODOLOGYThis Guideline was produced using the Appraisal of Guidelines forResearch & Evaluation (AGREE II) approach, 17,18 a structured approach to guideline production (see Table S1). This is designed to ensure appropriate representation of the full range of stakeholders, a careful search for and critical appraisal of the relevant literature, a systematic approach to the formulation and presentation of recommendations and steps to ensure that the risk of bias is minimized at each step of the process. The process started on April 2015 beginning with detailed face-to-face discussions agreeing on the process and the key clinical areas to address, followed by face-to-face meetings, and regular web conferences in which professional and lay representatives participated. | Clarifying the scope and purpose of the guidelinesThe scope of this EAACI Guideline is multifaceted...

show abstract

Section: Scitmentioning

confidence: 99%

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Roberts

Pfaar

Akdiş

et al. 2017

Allergy

564

705

View full text Add to dashboard Cite

show abstract

“…71 Patch tests should be read after 3 or 4 days and after 1 week. 72 An itching granuloma and a positive epicutaneous test are illustrated in Figures 3 and 4.…”

Section: Local Aluminum Reactionsmentioning

confidence: 99%

Vaccination and allergy: EAACI position paper, practical aspects

Nilsson

Brockow

Alm

et al. 2017

Pediatric Allergy Immunology

Self Cite

128

184

View full text Add to dashboard Cite

Immunization is highly effective in preventing infectious diseases and therefore an indispensable public health measure. Allergic patients deserve access to the same publicly recommended immunizations as non‐allergic patients unless risks associated with vaccination outweigh the gains. Whereas the number of reported possible allergic reactions to vaccines is high, confirmed vaccine‐triggered allergic reactions are rare. Anaphylaxis following vaccination is rare, affecting <1/100 000, but can occur in any patient. Some patient groups, notably those with a previous allergic reaction to a vaccine or its components, are at heightened risk of allergic reaction and require special precautions. Allergic reactions, however, may occur in patients without known risk factors and cannot be predicted by currently available tools. Unwarranted fear and uncertainty can result in incomplete vaccination coverage for children and adults with or without allergy. In addition to concerns about an allergic reaction to the vaccine itself, there is fear that routine childhood immunization may promote the development of allergic sensitization and disease. Thus, although there is no evidence that routine childhood immunization increases the risk of allergy development, such risks need to be discussed.

show abstract

“…The development of pruritic nodules at hyposensitization therapy injection sites has been attributed to aluminum. In one study, 8 of 37 children who underwent this therapy showed a contact allergy to aluminum (Netterlid et al, 2009). Iron is considered a rare cause of allergic contact dermatitis, though one case describing a 7-year-old boy with an iron allergy related to his orthopedic prosthesis has been reported .…”

Section: Other Metalsmentioning

confidence: 99%